Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-53282
Felip, E; Gridelli, C; Baas, P; Rosell, R; Stahel, R (2011). Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Annals of Oncology, 22(7):1507-1519.
PDF - Registered users only
The 1st ESMO Consensus Conference on lung cancer was held in Lugano, Switzerland on 21 and 22 May 2010 with the participation of a multidisciplinary panel of leading professionals in pathology and molecular diagnostics, medical oncology, surgical oncology and radiation oncology. Before the conference, the expert panel prepared clinically relevant questions concerning five areas: early and locally advanced non-small-cell lung cancer (NSCLC), first-line metastatic NSCLC, second-/third-line NSCLC, NSCLC pathology and molecular testing, and small-cell lung cancer to be addressed through discussion at the Consensus Conference. All relevant scientific literature for each question was reviewed in advance. During the Consensus Conference, the panel developed recommendations for each specific question. The consensus agreement on three of these areas: NSCLC pathology and molecular testing, the treatment of first-line, and second-line/third-line therapy in metastatic NSCLC are reported in this article. The recommendations detailed here are based on an expert consensus after careful review of published data. All participants have approved this final update.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Oncology|
04 Faculty of Medicine > University Hospital Zurich > Clinic for Thoracic Surgery
|DDC:||610 Medicine & health|
|Deposited On:||12 Jan 2012 16:16|
|Last Modified:||04 Dec 2012 13:53|
|Publisher:||Oxford University Press|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page